top of page
NCT05139225
NCT05431608
NCT02671448
NCT05139225
1/28
Multiple Myeloma Clinical Trials - Currently Recruiting
2022 - (R) NCT05431608
Phase 1: A Study of MCARH109 and MCARH125 in People With Multiple Myeloma
2022 - (R) NCT05393804
Phase 2: Trial of CART Ide-cel (bb2121) Status Post Hematopoietic cell Transplantation
2022 - (R) NCT05354557
Phase 2 - Study of Iberdomide in Multiple Myeloma Post ASCT Transplant
2022 - (R) NCT05130827
Phase 2: Plinabulin and Pegfilgrastim in People With Multiple Myeloma Undergoing ASCT
2022 - (R) NCT05032820
Phase 2: MM CAR-T to Upgrade Response BMT CTN 1902
2022 - (R) NCT05027594
Phase 1: Study of NMS-03597812 in Adult Pts With Relapsed or Refractory Myeloma
2022 - (R) NCT05024045
Phase 1 - Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
2021 - (R) NCT05139225
Phase 1: A Study of TTI-621 and TTI-622 in Combination With Daratumumab RRMM
2021 - (R) NCT05000450
Phase 1/2: Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell RRMM
2021 - (R) NCT04756726
Phase 1/2: CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma
2021 - (R) NCT04722146
Phase 1b - Teclistamab With Other Anticancer Therapies in Participants With Myeloma
2020 - (R) NCT04635735
Phase 1/2: Study of Ipilimumab After Stem Cell Transplantation in People With RRMM
2020 - (R) NCT04614636
Phase 1 - FT538 in Subjects With Advanced Hematologic Malignancies
2020 - (R) NCT04505813
Phase 1- Antigen-specific T Cell Therapy NEXI 002 Relapsed Refractory Multiple Myeloma
2020 - (R) NCT04497961
Phase 2: A Study of Health-Related Quality of Life with Daratumumab or Lenalidomide
2020 - (R) NCT04459416
Phase 3: Managing Pain and Symptom Burden Caused by Chemotherapy in Myeloma or Lymphoma
2020 - (R) NCT04394650
Phase 1 - CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in RRMM
2020 - (R) NCT04221178
Stopping Maintenance Therapy in People With Multiple Myeloma in MRD-Negative Remission
2020 - (R) NCT04093596
Phase 1 - ALLO-715 BCMA Allogenic CAR T Cells in relapsed Multiple Myeloma (UNIVERSAL)
2019 - (R) NCT04174196
Phase 2: A Study of Lenalidomide and CC-486 With Radiation Therapy in Plasmacytoma
2019 - (R) NCT04136756
Phase 1 - NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma
2019 - (R) NCT04133636
Phase 2 - Study of JNJ-68284528, CAR-T Therapy Directed Against BCMA in MM -CARTITUDE-2
2019 - (R) NCT03933735
Phase 1: ABBV-383 (TNB-383B) in Subjects With Relapsed or Refractory Multiple Myeloma
2019 - (Active) NCT04181827
Phase 3 -Cilta-cel vs Pom/Bort/Dex or Dara/Pom/Dex in relpsd. len ref MM CARTITUDE 4
2018 - (R) NCT03732703
Phase 1/2: Myeloma-Developing Regimens Using Genomics (MyDRUG)
bottom of page